

TOXICOLOGICAL PROFILE FOR IODINE

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

April 2004

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

A Toxicological Profile for Iodine, Draft for Public Comment was released in September 2001. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE,
Mailstop F-32
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.


Julie Louise Gerberding, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

Background Information

The toxicological profiles are developed by ATSDR pursuant to Section 104(i) (3) and (5) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) for hazardous substances found at Department of Energy (DOE) waste sites. CERCLA directs ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. ATSDR and DOE entered into a Memorandum of Understanding on November 4, 1992 which provided that ATSDR would prepare toxicological profiles for hazardous substances based upon ATSDR's or DOE's identification of need. The current ATSDR priority list of hazardous substances at DOE NPL sites was announced in the Federal Register on July 24, 1996 (61 FR 38451).

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can (Chemical X) Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.8	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.9	Biomarkers of Exposure and Effect
Section 3.12	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 498-0110 *Fax:* (770) 488-4178

E-mail: atsdric@cdc.gov

Internet: <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History — The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III *Medical Management Guidelines for Acute Chemical Exposures* is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 Phone: 770-488-7000 FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 Phone: 919-541-3212.

Radiation Emergency Assistance Center/Training Site (REAC/TS) provides support to the U.S. Department of Energy, the World Health Organization, and the International Atomic Energy Agency in the medical management of radiation accidents. A 24-hour emergency response program at the Oak Ridge Institute for Science and Education (ORISE), REAC/TS trains, consults, or assists in the response to all kinds of radiation accidents. *Contact:* Oak Ridge Institute for Science and Education, REAC/TS, PO Box 117, MS 39, Oak Ridge, TN 37831-0117 • Phone 865-576-3131 • FAX 865-576-9522 • 24-Hour Emergency Phone 865-576-1005 (ask for REAC/TS) • e-mail: cooleyp@ornl.gov • website (including emergency medical guidance): <http://www.ornl.gov/reacts/default.htm>

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 Phone: 202-347-4976 FAX: 202-347-4950 e-mail: AOEC@AOEC.ORG Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 Phone: 847-818-1800 FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

John Risher, Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Gary Diamond, Ph.D.
Steven G. Swarts, Ph.D.
Richard Amata, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for iodine. The panel consisted of the following members:

1. Dr. Lewis E. Braverman, Section Chief, Endocrinology, Diabetes, and Nutrition, Boston Medical Center, 88 East Newton Street, Evans 201, Boston, MA 02118;
2. Dr. Richard Leggett, Life Sciences Division, Oak Ridge National Laboratory, 11401 Glen Iris Lane, Knoxville, TN 37922-1744;
3. Dr. Ray Lloyd, Research Professor of Radiobiology, University of Utah School of Medicine, 6588 South Gold Medal Drive, Taylorsville, UT 84084-6964;
4. Dr. Marvin Rallison, Professor Emeritus of Pediatric Endocrinology and Metabolism, University of Utah School of Medicine, 1706 Oakridge Dr., Salt Lake City, UT 84106;
5. Dr. Elaine Ron, Senior Investigator, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, 6120 Executive Boulevard, EPS/7084, Rockville, MD 20852;
6. Dr. Kiyohiko Mabichi, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20852;
7. Dr. Noel R. Rose, Professor of Molecular Medicine, Johns Hopkins University, 615 North Wolfe St., Baltimore, MD 21205; and
8. Dr. Roy E. Shore, Professor and Director, Division of Epidemiology and Biostatistics, New York University School of Medicine, 650 First Ave., New York, NY 10016-3240.

These experts collectively have knowledge of iodine's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

DISCLAIMER.....	ii
UPDATE STATEMENT.....	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS	xi
PEER REVIEW.....	xiii
CONTENTS.....	xv
LIST OF FIGURES.....	xix
LIST OF TABLES.....	xxi
1. PUBLIC HEALTH STATEMENT.....	1
1.1 WHAT IS IODINE?.....	2
1.2 WHAT HAPPENS TO IODINE WHEN IT ENTERS THE ENVIRONMENT?.....	2
1.3 HOW MIGHT I BE EXPOSED TO IODINE?	3
1.4 HOW CAN IODINE ENTER AND LEAVE MY BODY?	4
1.5 HOW CAN IODINE AFFECT MY HEALTH?	4
1.6 HOW CAN IODINE AFFECT CHILDREN?	5
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO IODINE?	6
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO IODINE?.....	6
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?.....	7
1.10 WHERE CAN I GET MORE INFORMATION?.....	8
2. RELEVANCE TO PUBLIC HEALTH.....	11
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO IODINE IN THE UNITED STATES.....	11
2.2 SUMMARY OF HEALTH EFFECTS.....	12
2.3 MINIMAL RISK LEVELS.....	29
3. HEALTH EFFECTS.....	33
3.1 INTRODUCTION.....	33
3.2 DISCUSSION OF HEALTH EFFECTS FOR STABLE IODINE BY ROUTE OF EXPOSURE	35
3.2.1 Inhalation Exposure	37
3.2.1.1 Death	37
3.2.1.2 Systemic Effects	37
3.2.1.3 Immunological and Lymphoreticular Effects.....	37
3.2.1.4 Neurological Effects.....	37
3.2.1.5 Reproductive Effects	37
3.2.1.6 Developmental Effects	37
3.2.1.7 Cancer.....	37
3.2.2 Oral Exposure	37
3.2.2.1 Death	39
3.2.2.2 Systemic Effects	40
3.2.2.3 Immunological and Lymphoreticular Effects.....	65
3.2.2.4 Neurological Effects.....	70
3.2.2.5 Reproductive Effects	70

3.2.2.6	Developmental Effects	71
3.2.2.7	Cancer	71
3.2.3	Dermal Exposure.....	75
3.2.3.1	Death	75
3.2.3.2	Systemic Effects	75
3.2.3.3	Immunological and Lymphoreticular Effects	78
3.2.3.4	Neurological Effects	79
3.2.3.5	Reproductive Effects	79
3.2.3.6	Developmental Effects	80
3.2.3.7	Cancer.....	80
3.2.4	External Exposure.....	80
3.3	DISCUSSION OF HEALTH EFFECTS FOR RADIOACTIVE IODINE BY ROUTE OF EXPOSURE	80
3.3.1	Inhalation Exposure	81
3.3.1.1	Death	82
3.3.1.2	Systemic Effects	82
3.3.1.3	Immunological and Lymphoreticular Effects.....	82
3.3.1.4	Neurological Effects.....	83
3.3.1.5	Reproductive Effects	83
3.3.1.6	Developmental Effects	83
3.3.1.7	Cancer.....	84
3.3.2	Oral Exposure	84
3.3.2.1	Death	88
3.3.2.2	Systemic Effects	88
3.3.2.3	Immunological and Lymphoreticular Effects.....	97
3.3.2.4	Neurological Effects.....	99
3.3.2.5	Reproductive Effects	100
3.3.2.6	Developmental Effects	103
3.3.2.7	Cancer.....	109
3.3.3	External Exposure.....	127
3.4	GENOTOXICITY.....	127
3.5	TOXICOKINETICS.....	129
3.5.1	Absorption.....	129
3.5.1.1	Inhalation Exposure.....	129
3.5.1.2	Oral Exposure.....	130
3.5.1.3	Dermal Exposure.....	133
3.5.1.4	Other Routes of Exposure	136
3.5.2	Distribution	136
3.5.2.1	Inhalation Exposure.....	136
3.5.2.2	Oral Exposure.....	136
3.5.2.3	Dermal Exposure.....	140
3.5.2.4	Other Routes of Exposure	140
3.5.3	Metabolism	141
3.5.3.1	Inhalation Exposure.....	141
3.5.3.2	Oral Exposure.....	141
3.5.3.3	Dermal Exposure.....	148
3.5.4	Elimination and Excretion	148
3.5.4.1	Inhalation Exposure.....	148
3.5.4.2	Oral Exposure.....	148
3.5.4.3	Dermal Exposure.....	150
3.5.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	150

3.6	MECHANISMS OF ACTION	181
3.6.1	Pharmacokinetic Mechanisms	181
3.6.2	Mechanisms of Toxicity	188
3.6.3	Animal-to-Human Extrapolations	190
3.7	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	190
3.8	CHILDREN'S SUSCEPTIBILITY	191
3.9	BIOMARKERS OF EXPOSURE AND EFFECT	197
3.9.1	Biomarkers Used to Identify or Quantify Exposure to Iodine	198
3.9.2	Biomarkers Used to Characterize Effects Caused by Iodine	199
3.10	INTERACTIONS WITH OTHER CHEMICALS	201
3.11	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	205
3.12	METHODS FOR REDUCING TOXIC EFFECTS	206
3.12.1	Reducing Peak Absorption Following Exposure	207
3.12.2	Reducing Body Burden	207
3.12.3	Interfering with the Mechanism of Action for Toxic Effects	208
3.13	ADEQUACY OF THE DATABASE	209
3.13.1	Existing Information on Health Effects of Iodine	210
3.13.2	Identification of Data Needs	210
3.13.3	Ongoing Studies	215
4.	CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION	219
4.1	CHEMICAL IDENTITY	219
4.2	PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES	219
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	227
5.1	PRODUCTION	227
5.2	IMPORT/EXPORT	228
5.3	USE	228
5.4	DISPOSAL	229
6.	POTENTIAL FOR HUMAN EXPOSURE	233
6.1	OVERVIEW	233
6.2	RELEASES TO THE ENVIRONMENT	240
6.2.1	Air	240
6.2.2	Water	245
6.2.3	Soil	246
6.3	ENVIRONMENTAL FATE	248
6.3.1	Transport and Partitioning	248
6.3.2	Transformation and Degradation	252
6.3.2.1	Air	253
6.3.2.2	Water	255
6.3.2.3	Sediment and Soil	255
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	256
6.4.1	Air	256
6.4.2	Water	257
6.4.3	Sediment and Soil	260
6.4.4	Other Environmental Media	263
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	266
6.6	EXPOSURES OF CHILDREN	272
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	274
6.8	ADEQUACY OF THE DATABASE	278

6.8.1	Identification of Data Needs	278
6.8.2	Ongoing Studies	281
7.	ANALYTICAL METHODS	283
7.1	BIOLOGICAL MATERIALS	283
7.1.1	Internal Iodine Measurements	283
7.1.2	External Measurements	289
7.2	ENVIRONMENTAL SAMPLES	292
7.2.1	Field Measurements of Iodine	292
7.2.2	Laboratory Analysis of Environmental Samples	293
7.3	ADEQUACY OF THE DATABASE	305
7.3.1	Identification of Data Needs	306
7.3.2	Ongoing Studies	306
8.	REGULATIONS AND ADVISORIES	309
9.	REFERENCES	325
10.	GLOSSARY	497
	APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
	APPENDIX B. USER'S GUIDE	B-1
	APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
	APPENDIX D. OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY, AND BIOLOGY	D-1
	APPENDIX E. INDEX	E-1

LIST OF FIGURES

3-1. Levels of Significant Exposure to Iodine—Chemical Toxicity—Oral.....	48
3-2. Levels of Significant Exposure to Iodine—Radiation Toxicity—Oral.....	106
3-3. Pathways Uptake and Metabolism of Iodide in the Thyroid Gland.....	142
3-4. Thyroid Hormones and Metabolic Precursors	143
3-5. Pathways of Metabolism of Iodothyronines	145
3-6. Major Deiodination Pathways of Thyroid Hormones in Peripheral Tissues	146
3-7. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	152
3-8. Compartment Model to Represent Particle Deposition and Time-Dependent Particle Transport in the Respiratory Tract	154
3-9. Reaction of Gases or Vapors at Various Levels of the Gas-Blood Interface.....	157
3-10. The Human Respiratory Tract Model: Absorption into Blood.....	162
3-11. Structure of EPA (2002) PBPK Model of Iodine in Adult Male Humans and Rats.....	166
3-12. Berkovski (2002) Metabolic Model for Iodine.....	170
3-13. International Commission on Radiological Protection (ICRP) (1989) Metabolic Model for Iodine	173
3-14. National Radiological Protection Board of the United Kingdom Metabolic Model for Iodine	176
3-15. Johnson (1982) Metabolic Model for Iodine	178
3-16. Existing Information on Health Effects of Stable Iodine	211
3-17. Existing Information on Health Effects of Radioactive Iodine	212
6-1. Frequency of NPL Sites with Iodine Contamination.....	234
6-2. Frequency of NPL Sites with ¹²⁹ I Contamination.....	235
6-3. Frequency of NPL Sites with ¹³¹ I Contamination.....	236
6-4. Geochemical Cycle of Triad Elements (I, Br, Cl)	241
6-5. An Outline of the Movement of Iodine in the Environment.....	242

6-6. Diagram of the Global Iodine Cycle at Steady State Showing Environmental Compartments, Compartment Inventories in Grams (g), Transport Pathways, and Fluxes in Grams per Year (g/year).....	249
6-7. A Simplified Scheme of Iodine Cycling in the Marine Boundary Layer	254

LIST OF TABLES

2-1. Thyroid Doses and Dose Rates for Various Isotopes of Iodine.....	15
2-2. Risk Groups for Iodine-induced Hypothyroidism	17
2-3. Risk Groups for Iodine-induced Hyperthyroidism	19
2-4. Releases from Radioiodine-producing Events.....	22
3-1. Levels of Significant Exposure to Iodine—Chemical Toxicity—Oral.....	41
3-2. Levels of Significant Exposure to Iodine—Radiation Toxicity—Oral.....	104
3-3. Estimated Thyroid Radiation Doses in Populations Studied for Radioiodine-related Cancers	110
3-4. Binding Characteristics of Major Human Thyroid Hormone-Binding Proteins.....	138
3-5. Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity	156
3-6. Reference Values of Parameters for the Compartment Model to Represent Time-dependent Particle Transport from the Human Respiratory Tract	158
3-7. Chemical-specific Parameters for the Adult Male Rat and Human PBPK Models for Iodide.....	164
3-8. Properties of Human Iodothyronine Selenodeiodinases	187
3-9. Typical Reference Ranges for Serum Thyroid Hormones and TSH in Humans	200
3-10. Ongoing Studies on Health Effects of Radioactive Iodine	216
4-1. Chemical Identity of Iodine and Iodine Compounds.....	220
4-2. Physical and Chemical Properties of Iodine and Iodine Compounds.....	222
4-3. Percent Natural Occurrence and Radioactive Properties of Isotopes of Iodine.....	225
6-1. Approximate Releases of ^{129}I from Atmospheric and High Altitude Nuclear Weapons Tests.....	258
6-2. Concentration of Iodine, Chloride, and $^{129}\text{I}/^{127}\text{I}$ Ratio in Air and Precipitation as a Function of Location and Collection Time.....	261
6-3. Iodine Content in Specific Soil Types	262
6-4. Iodine Content in Missouri Soils as a Function of Depth and Parent Material	264
6-5. Estimated Average Iodine Intake for Adults in the United States	268
7-1. Analytical Methods for Determining Iodine in Biological Samples	284

7-2. Analytical Methods for Determining Radioiodine in Biological Samples	291
7-3. Analytical Methods for Determining Iodine in Environmental Samples	294
7-4. Analytical Methods for Determining Radioiodine in Environmental Samples	299
8-1. Regulations and Guidelines Applicable to Stable Iodine	310
8-2. Regulations and Guidelines Applicable to Radioactive Iodine	313
8-3. Dose Coefficients ^a (e(50)) for Intakes of Iodine Radionuclides.....	323